Are There Specific Subpopulations Who Benefit More From RSV Vaccines?
Our experts discuss the potential subgroups who might benefit from the vaccines and their safety profiles.
At the end of May, the FDA approved Moderna’s mRNA 1345 (mRESVIA) vaccine. With this latest approval, there are now 3 FDA-approved RSV vaccines for the prevention of lower respiratory tract disease caused by RSV infection in seniors.
As there are now 3 FDA-approved RSV vaccines, Contagion has developed a new short series titled, Special Report: Clinical Insights on Moderna's RSV Vaccine. We have asked RSV vaccine investigators to provide more insights about these immunizations. Ann Falsey, MD, professor of Medicine at the University Of Rochester School Of Medicine, and her colleague, Edward Walsh, MD, professor of Medicine at the University Of Rochester School Of Medicine lead a peer-to-peer discussion on the impact these vaccines may have in preventing this respiratory illness.
In the third episode, Falsey and Walsh discuss the potential subgroup populations who might benefit from RSV vaccines and the safety profile of the immunizations.
